ACADIA Pharmaceuticals (ACAD) Competitors $21.80 +0.42 (+1.96%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$22.40 +0.60 (+2.75%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACAD vs. SMMT, RDY, ASND, VTRS, MRNA, ROIV, QGEN, BBIO, ELAN, and VRNAShould you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Moderna (MRNA), Roivant Sciences (ROIV), Qiagen (QGEN), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. ACADIA Pharmaceuticals vs. Its Competitors Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Moderna Roivant Sciences Qiagen BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Summit Therapeutics (NASDAQ:SMMT) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Is SMMT or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to Summit Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -208.64% -181.28% ACADIA Pharmaceuticals 21.80%14.69%9.41% Which has higher valuation & earnings, SMMT or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit TherapeuticsN/AN/A-$221.32M-$1.01-21.22ACADIA Pharmaceuticals$957.80M3.84$226.45M$1.3316.39 Which has more risk and volatility, SMMT or ACAD? Summit Therapeutics has a beta of -1.13, indicating that its share price is 213% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Do analysts recommend SMMT or ACAD? Summit Therapeutics presently has a consensus target price of $31.29, indicating a potential upside of 45.99%. ACADIA Pharmaceuticals has a consensus target price of $29.12, indicating a potential upside of 33.57%. Given Summit Therapeutics' higher possible upside, equities research analysts plainly believe Summit Therapeutics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 5 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.44ACADIA Pharmaceuticals 1 Sell rating(s) 7 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.62 Does the media prefer SMMT or ACAD? In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 8 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.51 beat ACADIA Pharmaceuticals' score of -0.05 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in SMMT or ACAD? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryACADIA Pharmaceuticals beats Summit Therapeutics on 12 of the 15 factors compared between the two stocks. Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACAD vs. The Competition Export to ExcelMetricACADIA PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.68B$3.35B$6.12B$10.55BDividend YieldN/A2.28%5.66%4.70%P/E Ratio16.3922.2886.9626.71Price / Sales3.84417.06569.72225.61Price / Cash30.9346.3226.3031.09Price / Book4.959.9012.536.57Net Income$226.45M-$52.45M$3.30B$276.78M7 Day Performance2.25%5.05%3.53%1.98%1 Month Performance-13.70%10.61%6.77%9.13%1 Year Performance44.37%25.03%70.60%31.60% ACADIA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACADACADIA Pharmaceuticals4.4736 of 5 stars$21.80+2.0%$29.12+33.6%+44.4%$3.68B$957.80M16.39510SMMTSummit Therapeutics3.0418 of 5 stars$19.10+1.1%$31.87+66.8%+12.3%$14.19B$700K-18.91110RDYDr. Reddy's Laboratories3.256 of 5 stars$14.59-1.9%$16.95+16.2%-9.5%$12.18B$3.81B22.1127,811Positive NewsASNDAscendis Pharma A/S3.2632 of 5 stars$196.42-0.6%$244.36+24.4%+43.0%$12.10B$393.54M-38.071,017Positive NewsHigh Trading VolumeVTRSViatris1.1339 of 5 stars$9.79-1.1%$10.40+6.2%-12.1%$11.41B$14.12B-3.3832,000MRNAModerna4.1571 of 5 stars$26.56+5.2%$41.81+57.4%-52.7%$10.33B$3.06B-3.535,800ROIVRoivant Sciences3.5284 of 5 stars$14.94-0.7%$19.94+33.5%+42.1%$10.20B$29.05M-21.34860QGENQiagen4.4731 of 5 stars$45.72-0.5%$49.69+8.7%+10.5%$10.16B$2.04B27.015,765Analyst DowngradeBBIOBridgeBio Pharma4.3609 of 5 stars$51.54-1.6%$63.94+24.1%+109.5%$9.85B$235.81M-12.60400ELANElanco Animal Health2.6376 of 5 stars$19.08-0.6%$17.33-9.2%+40.8%$9.48B$4.48B22.199,000VRNAVerona Pharma PLC American Depositary Share1.9128 of 5 stars$106.25+0.2%$109.00+2.6%+233.6%$8.69B$221.67M-107.3230Positive News Related Companies and Tools Related Companies Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Moderna Alternatives Roivant Sciences Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACAD) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
